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We here apply a control analysis and various types of stability analysis to an in silicomodel
of innate immunity that addresses the management of inflammation by a therapeutic
peptide. Motivation is the observation, both in silico and in experiments, that this therapy
is not robust. Our modeling results demonstrate how (1) the biological phenomena of
acute and chronic modes of inflammation may reflect an inherently complex bistability
with an irrevertible flip between the two modes, (2) the chronic mode of the model
has stable, sometimes unique, steady states, while its acute-mode steady states are
stable but not unique, (3) as witnessed by TNF levels, acute inflammation is controlled
by multiple processes, whereas its chronic-mode inflammation is only controlled by TNF
synthesis and washout, (4) only when the antigen load is close to the acute mode’s
flipping point, many processes impact very strongly on cells and cytokines, (5) there is no
antigen exposure level below which reduction of the antigen load alone initiates a flip back
to the acute mode, and (6) adding healthy fibroblasts makes the transition from acute to
chronic inflammation revertible, although (7) there is a window of antigen load where
such a therapy cannot be effective. This suggests that triple therapies may be essential
to overcome chronic inflammation. These may comprise (1) anti-immunoglobulin light
chain peptides, (2) a temporarily reduced antigen load, and (3a) fibroblast repopulation
or (3b) stem cell strategies.
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INTRODUCTION
When activated leukocytes engage in host defense against an invading antigen, the process of
innate immunity often reverts disease progression within a fortnight (1, 2). Occasionally, this
acute and transient inflammation turns into a chronic inflammation with local tissue damage
(3–5). The chronic inflammation consists first of an accumulation phase, which is characterized
by rapid recruitment of immune cells (i.e., macrophages, eosinophils, neutrophils, mast cells).
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This is followed by the activation phase, where various cytokines
and chemokines are released by immune cells. Then, a subversion
phase follows, when the chronic inflammation subsides. Chronic
inflammation can last many months and even years, continuing
even in the absence of the invading foreign antigen. This lengthy
period can cause much progressive damage to normal tissues
and thereby invoke numerous functional, hence financial and
societal, complications, affecting the patient, the family, and the
healthcare system (6–8). Meanwhile, the slower but more specific
adaptive immunity process will begin, but this is beyond the
scope of this paper and its mathematical model.
In many studies of immunity, in silico modeling has been
used. One modeling avenue has aided a structure-based drug
design, focusing on single molecules and their interactions, for
instance, identifying the antagonists of CCR4 in silico, validated
by injection together with vaccines in vivo (9). Another branch
of modeling focuses on the networks within any one particular
cell that are of immunological importance. This comes close
to more conventional systems biology (10). The present paper
treads a third avenue, i.e., models of the dynamics of the
intercellular networks in immunology. Mathematical models
based on ordinary differential equations (ODEs) have already
been used to study B cell responses (11, 12), T cell responses
(13, 14), and natural killer (NK) cell mechanisms (15, 16), but
largely in adaptive immunity. Various software environments
already exist for modeling immune system paradigms (17). For
example, the immune cell simulator (18), the synthetic immune
system (19), and the basic immune simulator (20) provide
platforms for creating and then simulating the performance of
virtual immune systems consisting of a variety of cell types and
their interactions. These models and environments have not yet
championed the systems biology approach of examining how
molecular and (in this case) cellular interaction mechanisms lead
to the functional properties of the network, of comprehensive
maps of the interaction network, of systematic notation of such
maps, of allowing the implementation of genomics information,
and of dynamic models directly exchangeable through SBML
nor have they connected systems biology methodologies such as
control analysis with its summation laws.
Such systems biology strategies, which typically integrate
quantitative experimental information with such network
modeling, may help to construct network–mechanistic
understanding of the immune cells’ roles (21), especially if
the models consist of realistic processes. On the other hand,
immunology may also help in the development of multicellular
systems biology. Immune cells which are involved in host
defense can be isolated from living organisms, cultured in
vitro, and reconstituted into another living organism in vivo.
Consequently, innate immunity may be one of the few areas
in human biology where complex system properties arising
through “multicellular system emergence” can be identified
and understood in an integral experimental and computational
analysis. Such emergent properties are likely to include the
maintenance of phenotypic stability in the face of perturbations
caused by infection and inflammation, resulting from both
positive and negative feedback loops that together accomplish
a strong yet limited response, but they should also include
deviations from such stability, which may then resemble human
pathologies such as chronic inflammation and allergy.
Although from the perspective of understanding the immune
response, innate immunity has already been proposed a while
ago to be most suitable for systems biology studies (10),
the number of mathematical models focusing on this innate
immunity is still limited (22), yet the innate immune system
plays an important role in effective host defense against bacterial
and viral infections (23, 24) and possibly in allergies and
tumorigenesis, and there may already be sufficient information
to construct explicit mechanism-based systems biology models.
A comprehensive map of IgE-mediated mast cell activation (25)
might be used to explore both the intracellular and population
dynamical properties of the corresponding section of the immune
system, and the experimental field is now reporting genome-
wide experimental data sets, which systems biology can integrate
and help understand in terms of the emergence of function
(10). One pipeline of already existing mathematical models
of innate immunity has only four, rather abstract, variables,
i.e., “inflammation,” “damage,” “initiating event,” and “anti-
inflammation” (26). This pipeline already shows that complex
functional behavior emerges at certain values of the abstract
parameters. These models are simplifications of a much more
detailed and explicitly mechanistic model that enabled in silico
simulation of clinical trials of anti-TNF (TNF = TNF-α, i.e.,
tumor necrosis factor alpha) agents as medicine against sepsis
(27). The simulations helped explain why so many of these
clinical trials have failed (28): inter-patient variability and the role
of multiple factors rather than of the single drug target (27). More
recently, Petersen et al. (29) put in place a deep reinforcement
learning strategy, automatically personalizing this type of model
for use in multifold cytokine therapies. Mavroudis et al. (30)
showed how stochasticity can be taken into account, which they
did essentially for the simpler four-variable model referred to
above. Other authors extended these models to include spatial
dimensions and multiscale aspects (22, 31), the latter authors
shifting to a Boolean approach.
The models have already been used in the context of
applications to actual diseases and their therapies. Prince et al.
(32) combined an in silico endeavor with an in vivo approach
to elucidate the complexity of inflammation in CD-14-deficient
mice subjected to Gram-negative lipopolysaccharides and
cannulation. Rullmann et al. developed the Entelos Rheumatoid
Arthritis Physiolab platform to predict the therapeutic effects
of drugs (33). Separately, the National Institute of Allergy and
Infectious Diseases established the Systems Biology for Infectious
Diseases Research (SysBio) program that facilitates research
lines in systems influenza, systems virology, systems biology
of enteropathogens, and Mycobacterium tuberculosis systems
biology (34), and there is much application in the realm of
tumorigenesis [e.g., (35–37)].
We became interested in applications with respect to
the curing of inflammation using peptides interfering with
extracellular regulatory pathways (34). This came about after
realizing that immunoglobulin light chains may help elicit
inflammation (38) and occur at increased levels in inflammatory
pathologies (39). Anti-FLC peptide F991, a functional inhibitor
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of the immunoglobulin light chain either in its free form or when
in IgE (40), appeared to be able to slow down the progression
of colitis, presumably by reducing inflammation (41), but in
our own hands, the results were variable. To try to understand
both the effect and its complexity/variability, we constructed a
detailed differential equation model (42). This model enacted
inflammation as a set of explicit positive and negative regulatory
loops involving host tissue (fibroblasts), B cells, mast cells, and
microbial cells, as well as TNF, circulating antigen, IgE receptors
on the mast cells, and immunoglobulin light chains, free or
in igE. As detailed in Abudukelimu (42), the model was based
on well-known interactions in innate immunity, on reasonable
physical chemical parameter values (inclusive of consistency
with diffusion limitation and equilibrium binding constants),
and validated in the sense of predicting known features of
innate immunity. In making one of these predictions, we plotted
the model-predicted TNF level as marker of the intensity of
inflammation vs. antigen dosage. We observed a sustained low
level of inflammation at low antigen dosage, until at a certain
antigen dosage the TNF flipped to a much higher level. Bringing
the antigen dosage back down did not bring the TNF level
down. Only at a very low antigen dosage did the TNF lead
to low inflammation levels. Then, two surprises emerged: first,
a minor increase in antigen dosage already pushed the TNF
back to high inflammation levels and, second, simulated F991
peptide therapy worked only transiently. It seemed that the
model behaved non-robustly when changing the antigen dosage
or when treating with the peptide. In the earlier paper (42), we
noted these phenomena and suggested that bistability might be at
the origin of this, but we did not analyze and prove this further.
When subsequently we began to analyze the phenomenon in
more detail, we found that it was not just a simple bistability
but much more complex than that, the complications having
potential impact on innate immunity, allergies, and therapies
thereof. It is these phenomena that we shall embark on here
with more targeted systems biology methodologies. Non-unique
behavior of non-linear models has been understood by stability
and bifurcation analysis, e.g., in epidemiology, physiology, and
immunology (26, 43). Such analyses can reveal that a model
predicts multiple, stable or metastable, steady, and oscillatory
or chaotic attractor “states.” Parameter sensitivity analysis can
then be used to establish how readily the network function
becomes critical as a parameter is changed. In the context of
immunology, sensitivity analysis has, for instance, been used
to evaluate the influence of maternal adaptive immunity on
the time dependence of infection and on its consequences for
serology (44) to identify the relative importance of the molecular
components in coupled MAPK and PI3K signal transduction
pathways (45), for the NF-κB signaling network (46), in an
immune-based model of Helicobacter pylori infection (47), and
in analyzing the T cell response to antigen (48). An approach
related to sensitivity analysis is metabolic control analysis, which
is limited to sensitivities with respect to process activities (49–51).
This comes with the advantage that, for stationary states, control
coefficients sum up to fixed totals of 1, 0, and −1 for control of
concentrations, fluxes, and cycle times, respectively (49, 51). This
helps to organize questions such as whether the total control of
network performance resides in a single “rate-limiting” step or
is distributed over many processes in the network. If the latter
case upholds, this begs the question which components have
the highest control coefficients and thereby surface as the better
targets for therapeutic interventions (50).
Where the computations in our previous paper (42) observed
some sort of complex bistability in the modeled innate immunity,
they did not elucidate what type of complexity it was and
how it could be controlled. In this paper, we implemented
stability, bifurcation, and control analysis to that model of innate
immunity (42) with the aim of clarifying (1) why and how it
exhibits its complex dependence on antigen dosage as well as on
the history thereof, (2) why the F991 peptide may act erratically,
(3) if there might be a way to increase the robustness of this
peptide therapy, and (4) which should be the best targets for
intervention. We report on a subtle balance between apparent
stability and bistability, a threshold between acute and chronic
inflammation, fibroblasts playing a special role in preventing
or reverting an irrevertible transition to chronic inflammation,
and a wide distribution of control implying multiple potential
drug targets.
METHODS
The Dynamic Model
The dynamic model used was defined and illustrated in
Abudukelimu et al. (42). Its node and balance equations, leading
to ODEs, were encoded in Copasi software (52). Precisely
the same equations and parameter values were used in the
present paper (with minor exceptions for TNF and MMP7, as
documented in Supplementary Table S1). The model’s Copasi
and SBML code are in the Supplementary Material of this paper
and in the JWS-Online model repository. The model has B cells,
mast cells, fibroblasts, and bacteria as cellular components and
cross-reactive antigen (CRA), protease, tumor necrosis factor-α
(TNF), MMP7, MMP8, free light chains (FLCs or IgE) and their
receptors on mast cells, and FLC-binding peptides as molecular
components. There is an influx of CRA and, where indicated,
an influx of fibroblasts or presence of bacteria. Molecular
components, fibroblasts, and (if present) bacteria wash out at a
certain rate but are also produced by the biology. The parameter
“total space” is 1,000 fM, such that fibroblasts could only grow
to a concentration of 1,000 fM. This corresponds to 1.7 pl per
cell, which is when they should occupy “total space” and be
contact-inhibited in three dimensions.
Units in the model are as indicated, typically picomolar
(pM, 10−12 moles/liter), femtomolar (fM, 10−15 moles/liter), or
attomolar (aM, 10−18 moles/liter). The results being reported
in terms of these real (rather than “arbitrary”) units should
not be taken to suggest precision. Due to the uncertainty in
parameter estimates, our results are unlikely to be precisely
correct, yet expressing the results in this manner allows for a
better comparison between them.
Sensitivity and Control Analysis
Control coefficients (a type of sensitivity coefficients or response
coefficients) (51) were calculated for levels of model components
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such as TNF at steady state considering their control by process–
rate parameters such as the influx rate of CRA. They were defined
as the log–log derivatives of concentration with respect to rate
constant (53) and computed numerically through Copasi. They
are represented as a capital C followed by the controlled variable
as superscript and by the controlling parameter as subscript.
Stability Analysis of Steady States
In order to determine the stability of the system, numerical
simulations were performed by using Copasi in two modes.
In one we asked it to compute the steady state as well as the
stability properties at steady state in terms of the eigenvalues.
When any eigenvalue was reported by Copasi to have a positive
real part, we report that the state is unstable. Every steady-state
computation was followed by a calculation of time dependence
starting from that steady state as initial condition. Only if that
second computation confirmed that the system did not evolve
away from that initial condition do we report the state as stable.
Depending on conditions, the computations produced one or
two stable steady states. In the latter case, there often appeared
to be a third unstable steady state, which Copasi could find in its
steady-state mode but not in its time-dependence mode.
We did not perform a complete scan of initial conditions
space nor of the parameter space since it is impossible to obtain
the ultimately necessary resolution when there is such high
dimensionality. We therefore cannot exclude that there are more
than three steady states in the model for any given value of CRA
influx rates.
The Model and a Caveat
This paper will use our model of innate immunity (42), which
constitutes an attempt to be realistic in terms of elemental
mechanisms and parameter values. Parameter values and kinetic
equations are not phenomenological but refer to what is or
could be true, or at least possible, e.g., in the sense of diffusion
limitation, as rationalized in Abudukelimu et al. (42).
Figures
Computations were performed for many parameter values, and
the results are mostly shown as very small dots, which are then
connected by more visible straight lines. The points on the
connecting lines have not been computed but interpolated.
RESULTS
Instability, Flares of Infection, and a
Therapy Thereof
When added to our model of innate immunity (42), infecting
bacteria grew quasi-exponentially until they were overrun by
an even faster-growing immune response causing a virtually
complete elimination of bacterial cell count in what seemed
to be a steady state (Figure 1A) (42). In the stability analysis
of the present study, we found that that final state was not a
stable steady state however (Figure 1A); the steady state had one
real eigenvalue that was positive (0.005/min). This resulted in
spurious resurgence of the infection in the in silicomodel, which
only became evident when we ran the model for appreciable
duration. Bursts of bacterial growth then arose long after the
infection appeared to have been dealt with by the innate immune
system (results not shown).
A similar phenomenon has been reported by Kumar et al.
(54) but attributed to computational problems. We therefore
evidenced that such computational problems do not seem to
be responsible for our results. For Figure 1D, for instance, the
minimum obtained in between the first and the second peak
amounted to 0.0007 fM of bacteria (about 0.4 million per liter),
i.e., not at all close to other small numbers in some of our other
robust computations (see below) which were 10−50 fM or smaller.
This number (0.0007 fM) did not change when we varied the step
size or tolerance settings of Copasi. Moreover, the steady-state
algorithm led to an unstable steady state (at zero bacteria), with a
complex eigenvalue with positive real part of 0.0018/min.
We therefore reckon that the phenomena of recurrent bursts
of infection could be realistic and reflect the difficulty of the
innate immune system in eliminating the very last bacteria. In the
model, the bacteria were lysed by proteases produced by activated
mast cells. This activation was part of a positive feedback loop
and should vanish upon the virtual disappearance of the bacteria.
This produced the paradoxical situation that the regulation that
had been eliminating the bacteria disappeared when the density
of the bacteria became low, enabling the bacterial population
to re-emerge.
We expected that a steady influx of protease killing the
bacteria (in addition to the protease produced by activated mast
cells) should reduce the maximum level of infection and get rid
of it more quickly and more definitively. Figures 1B–D show
that our expectations were only partly correct: the amplitude
of the bacterial infection was reduced by the extra protease, as
expected, but now multiple bursts of bacterial growth occurred
within the time span considered at a frequency that increased
rather than decreased with the magnitude of the protease influx.
The highest influx rate of protease that we tested was detrimental
to the bacteria and produced a steady state without recurrence
(Figure 1E). At this protease influx rate, the steady-state solution
only had eigenvalues with negative real parts (the largest was
−0.0005/min). A strong steady influx of protease appeared to be
a “therapy” of the flares of inflammation.
Bistability and Bimodal Control
Having identified bacterial growth as a major source of instability
in our model, we wondered if there were more such sources.
We therefore removed the bacteria from our computations and
replaced them with a constant influx of antigen, which we call
cross-reactive antigen. In our model, this CRA was already
secreted by fibroblasts that are activated by TNF.
We then increased this CRA influx in steps, starting from
zero. Up to a CRA influx rate of 16.7 fM/min, the inflammation
intensity, as evident from TNF levels, increased only slightly
with increasing CRA challenge (42). At just over 16.7 fM/min,
the inflammation suddenly intensified, as witnessed by a strong
increase in TNF levels and a strong decrease in fibroblast
levels. When the CRA influx rate was reduced subsequently,
the system stayed in the high inflammatory mode and only
returned to states with low TNF levels at very low CRA
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FIGURE 1 | Resurgence of bacterial infection in the in silico model of innate immunity. The standard model (Supplementary Table S1) was re-run at various
magnitudes of the steady influx of a protease that could kill the bacteria. Protease influx was (A) zero, (B) 0.001 fM/min, (C) 0.003 fM/min, (D) 0.005 fM/minm, or (E)
1.0 fM/min. Only for (E) was a stable steady state reported, with the largest eigenvalue equaling −0.0005/min. For the other four cases, unstable steady states at zero
levels of bacteria were computed with positive real parts of one or (if complex) two eigenvalues. Supplementary Table S2 shows concentrations computed at 4 days
and at steady state.
challenges (see also Figure 4B below). At any CRA influx rate
below 16.7 fM/min, the system could exist in either of two
stable steady states (42), an apparent case of dynamic bistability
(55, 56). We refer to these two families of steady states as
two “modes” of inflammation, i.e., the “chronic” mode and
the “acute” mode (42), for the multiple reasons that we shall
detail below.
For each of these modes, we wondered whether inflammation
is controlled by a single “rate-limiting” process, such as the
influx of antigen, and if so, whether this controlling process
differed between acute and chronic inflammation. To answer
these questions, we performed a control analysis of both the
acute and the chronic states at an intermediary antigen load of
1 fM CRA/min. For the acute mode of inflammation, control was
distributed over many but certainly not all of the participating
processes. As expected, there was full positive control of TNF
levels by TNF production and full negative control by TNF
washout, but also many other processes exercised control over
the inflammation’s TNF level (Figure 2, the green bars). This
included positive control by release of the pro-inflammatory
cytokine MMP7 by fibroblasts and an even stronger negative
control byMMP8 released by the fibroblasts, as well as substantial
control by CRA clip off from fibroblasts, by FLC production by
B cells, by CRA influx and degradation, and by the washout of
various factors. The absence of control by the fibroblast life cycle
is understandable on the basis of the phenomenon that fibroblast
levels in acute inflammation are pretty close to their maximum
defined by contact inhibition (42). By contrast, in the chronic
inflammationmode, all control resided in the production bymast
cells of TNF and in the washout of TNF (orange bars in Figure 2).
This was because all mast cells were already fully active in TNF
production (not shown).
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FIGURE 2 | Bimodal control analysis: distribution of control of acute and chronic inflammation. Concentration control coefficients for TNF were calculated for the
acute and chronic mode of inflammation and indicated as blue and red bars, respectively, with their magnitudes corresponding to their projections onto the abscissa.
The standard model was used at CRA influx = 1.0 fM/min (see Supplementary Table S3). In the chronic mode, the concentration control coefficients for kinetic
activities annotated by “AO” were not computable because the controlling parameter was a property of a species present at a concentration too close to zero. These
control coefficients correspond to zero. Also in the other cases where no bar is visible (including the sum case) the corresponding control coefficient equals 0.0. This
Figure was created using both Supplementary Table S3 (the concentration control coefficients for acute) and Supplementary Table S4 (the concentration control
coefficients for chronic cases).
When also computing the control coefficients for the other
concentrations, and with one set of exceptions, we mostly (see
below) found all control coefficients referring to the dependence
of concentrations on process activities to be “moderate,” where
“moderate” refers to absolute values not far beyond 2, with
1 being the magnitude of total control of any flux by all
reaction activities (57). The exception was for the acute mode
of inflammation at one particular magnitude of the influx
of antigen, where multiple control coefficients attained high
absolute magnitudes. Figure 3A shows that while TNF levels
were becoming sensitive to the zero-order reaction rate constant
of CRA influx, when that was increased from 0.1 to 10 fM/min,
they became ultrasensitive when the influx rate approached
the threshold (42) at 16.7 fM/min. Close to this CRA influx
rate there appeared to be a singularity where the control
coefficients amounted to infinity, corresponding to the vertical
jump observed for the acute inflammation branch in Figure 4A.
For CRA influx above this threshold level, where the TNF level
had increased to that characteristic of high inflammation (see
Figure 4A), the TNF-by-CRAinflux control coefficient dropped
to zero (Figure 3A). In the high inflammation state, the TNF
level was “maximal” at 50 pM and insensitive to the amount of
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FIGURE 3 | Bimodal control analysis of the innate inflammation model at various antigen challenges. A first mode of concentration control coefficients of steady-state
magnitudes of TNF with respect to (A) CRA influx rate and (B) TNF production rate constant was obtained when starting from a steady state at a very low CRA influx
rate (0.001 fM/min) and then increasing the CRA influx to the level indicated on the abscissa (this procedure defines the “acute inflammation mode” of the model; cf.
Figure 4A). A second mode of control coefficients of steady-state magnitudes of TNF with respect to (C) CRA influx rate [see also (42)] and (D) TNF production rate
constant was obtained when starting from a steady state at high CRA influx rate (30 fM/min), then decreasing the CRA influx to the level indicated on the abscissa (this
procedure defines the “chronic inflammation branch” of the model; cf. Figure 4B). Control coefficients were calculated for the CRA influx value corresponding to each
red point. The blue straight lines connect these computed points.
CRA flowing into the system from the outside. In the chronic
mode above, at a CRA influx of 0.1 fM/min the network itself
sustained a high CRA and FLC, enough to fully saturate and
activate the mast cells, leaving no opportunity for CRA influx
to affect the inflammation. Figure 3C shows that for the chronic
mode of inflammation, i.e., when we stepwise reduced the CRA
influx from 30 fM/min down to 0.001 fM/min and computed the
steady state at each step, the sensitivity of the TNF level to influx
of CRA was indeed zero at first but then regained its sensitivity,
but only at CRA influx rates below 0.1 fM/min. This occurred
as the high TNF levels of around 50 pM began to decrease
(Figure 4B). At CRA influxes below 0.01 fM/min, the control
coefficient of TNF levels to the CRA influx rate then approached
2 (Figure 3C), much higher than at the same CRA influx values
in the acute mode (Figure 3A). The magnitude of the control
coefficients depended strongly on whether the system operated
in the acute or in the chronic mode of the system, the TNF level
in the chronic mode being much less sensitive to changes in CRA
influx at intermediate CRA influx rates and much more sensitive
at low CRA influx (Figures 2, 3A,C). This is why we call this a
“bi-modal” control analysis.
In the chronic mode, no singularities were observed. This
implies that, whereas at CRA influx rates immediately above
the singularity in the acute mode at 16.7 fM/min the system
jumped from the low inflammation model to the mode of high
inflammation, the reverse would not happen as a jump back
to the same low inflammation mode at any low CRA influx
rate. Once the system was caught in the high inflammation
mode, it would stay there. This is the first reason why we called
the high inflammation mode the “chronic mode” and the low
inflammation mode “acute” (see also below).
Figure 3D shows that, in the chronic mode, TNF levels
were proportionally sensitive to the reaction rate constant
of TNF production throughout the range of CRA influx
rates again, but now for the intermediate CRA influx rates,
highly different from what was observed for the acute mode
(Figure 3B). Supplementary Table S3 shows all concentration
control coefficients for acute inflammation. Control was
always distributed over multiple components, and expected
summation laws (51) were observed except when variables were
close to zero, which caused numerical inaccuracy problems.
Supplementary Table S4 does the same for the chronic mode.
Bistability
The singularities in the control coefficients reminisce a bistable
dynamic system (43, 50) in which, for a range of values of a so-
called bifurcation parameter, there are two stable steady states.
Which of these steady states is attained then depends on the
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FIGURE 4 | Complex stability properties of the innate inflammation model. Stepwise computations again using the model of Abudukelimu et al. (42), starting from the
0.001 fM/min CRA influx steady state for the acute mode and step-wise increasing that influx or starting from the 30 fM/min CRA influx steady state for the chronic
mode and stepwise decreasing that influx. In each step, the CRA influx rate was altered to the next value indicated on the abscissa, and a new steady state was
calculated. (A) The steady-state TNF levels for the acute mode are plotted as ordinate. These were subsequently taken as initial conditions with the exception of the
TNF level, which was equated either to 100 or to 0.0001 pM before simulating the system’s evolution to steady state in time. The dashed arrow describes the
evolution of the TNF level. Taking the final values as initial conditions, the steady-state mode of Copasi was used to confirm that the final condition was stable and
steady, with the exception of the states at 1 and 10 fM/min where these initial conditions led to a relaxation to the upper, “chronic” state, as indicated by the small
arrows at the top. In these cases, initial conditions of 10 pM rather than 100 pM TNF did lead to a relaxation to the lower, “acute” state. (B) The same as in (A) but
now for the chronic branch.
system’s initial state, in the simplest case on the initial value of
a single bifurcation variable. The dashed arrows in Figures 4A,B
show that both modes of steady state were highly stable to TNF
perturbations. An increase in TNF to 100 pM, or a decrease to 0.1
fM, was followed by a relaxation back to the steady-state value.
Exceptions were the acute states at CRA influx rates in excess
of 0.1 fM/min, where these perturbations directed the system to
the chronic mode. Still for the acute mode states at 0.5, 1, 5, and
10 fM/min, a more modest perturbation to 10 pM of TNF was
followed by a relaxation back to the acute state. The acute mode
was locally stable throughout (as was the chronic mode of states).
The model has many more variables however, and physically
steady states should be stable toward small perturbations of any
variable. An effective way of checking thismore complete stability
is to calculate the eigenvalues of the system at the steady state.
Stability is obtained if the real parts of all the eigenvalues are
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FIGURE 5 | Stability analysis by monitoring steady-state eigenvalues in various network modes. Acute mode (solid blue line): The steady state computed for a CRA
influx rate of 0 pM, and a healthy fibroblast level of 1 pM was taken as starting point from which a new steady state was computed after increasing the CRA influx rate
to a value on the abscissa successively. The ordinate shows the computed largest (real part of the) eigenvalue. Chronic mode (solid red line): The steady state
computed for a CRA influx rate of 30 fM/min, and a healthy fibroblast level of 1 pM was taken as starting point from which a new steady state was computed after
reducing the CRA influx rate to the value indicated on the abscissa. The ordinate shows the computed largest (real part of the) eigenvalue. For CRA influxes at and
below 0.01 pM, the steady states were reported as unstable, but subsequent time integrations and steady-state computation altered neither the eigenvalues nor the
TNF level. Chronic mode re-increasing antigen exposure after maximal reduction (gray dots). From the endpoint of the computations for the red line (i.e., at CRA influx
of zero and extremely low TNF and healthy fibroblast levels), the CRA influx was increased; the steady-state eigenvalues were computed and shown as gray circles.
Fibroblast-fixed chronic mode (yellow line): Largest eigenvalues for the chronic steady state were computed similarly as for the red line but with the healthy fibroblast
level fixed to zero. The computed steady states were now reported as stable.
negative in sign. The stability analysis by Copasi reported that the
steady states of the acute mode were stable throughout, i.e., also
at the high TNF levels obtained for CRA influx in excess of 16.7
fM/min; their largest eigenvalues were always negative. As shown
by the blue line in Figure 5, below the CRA influx threshold of
16.7 fM/min the real part of the largest eigenvalue amounted to
−0.0005 /min, corresponding to a relaxation to the steady state
within a couple of days. At the more intense inflammation above
that antigen-influx threshold, the inflammation was stable at an
eigenvalue corresponding to a relaxation in a couple of hours. At
the threshold itself the largest eigenvalue became zero, making
the slowest relaxation very slow.
In the chronic mode (red line in Figure 5), while reducing
the antigen load the eigenvalue remained ∼-0.01/min, until
at a dosage of 0.1 fM/min it increased to become positive at
around 0.0005 fM/min. Accordingly, no stable steady state was
reported for CRA influx levels below 0.01 fM/min. This was
due to extremely low and variable fibroblast levels. Running
the time dependence simulation did not cause the system to
move away substantially from these low fibroblast levels and
positive eigenvalues, for instance, to the stable steady state
corresponding to the acute mode of inflammation. When fixing
the healthy fibroblast level in the model to zero, a stable steady
state was obtained at the same level of TNF, corresponding to the
chronic inflammation mode, the largest eigenvalue decreasing to
−0.009/min (yellow line in Figure 5). Moreover, when increasing
the antigen dosage from below 0.0001 fM/min back up by
successive factors of 10 (gray dots in Figure 5), the eigenvalue
retraced its steps along the line corresponding to the chronic
inflammation mode as the TNF level itself did (Figure 4B).
Notably, the unstable steady state described here for the chronic
mode did not correspond to the unstable steady state in between
the two stable steady states to be discussed below; it corresponded
to one of the two stable steady states. We conclude that in essence
(i.e., save a fibroblast level fluctuating at virtually zero), both the
acute and the chronic modes of steady state were stable.
Hysteresis
As already apparent from the above results, bistability can come
with hysteresis. Indeed when the CRA influx rate was reduced
from 30 fM/min down to rates below 16.8 fM/min, the TNF
levels remained high until only at CRA influx levels below 0.1
fM/min did they start to decrease (Figure 4B). For CRA influx
rates between 16.8 and 0.001 fM/min, the steady-state TNF level
depended on whether the initial state for the computation had
been 0 fM/min (the acute mode; Figure 4A) or 30 fM/min (the
chronic mode; Figure 4B); the system was hysteretic rather than
Markovian, i.e., it remembered its history.
Because in Figure 4B the inflammation remained intensive
all the way down the CRA influx rates of 0.03 fM/min, i.e.,
notwithstanding a 1,000-fold reduction of the antigen challenge,
it appeared to be hard to get rid of. Moreover, even though it
might seem that the blue lines of Figures 4A,B converged toward
a common point at 0.1 aM/min CRA influx and a TNF of 0.5 fM,
they did not merge, neither for further reduction of CRA influx
rates nor for subsequent re-increase of CRA influx rates; the
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two lines did not intersect, but crossed, consolidating hysteresis.
This further motivates our reference to the line in Figure 4B as
the “chronic inflammation” mode. We likewise continue to refer
to the steady states depicted in Figure 4A for CRA influx rates
below 16.7 fM/min as the “acute inflammation mode.”
Such hysteresis could be explained by the acute and the
chronic modes differing from each other in some other property
than TNF level at this apparent intersection point. Indeed the
fibroblast levels were high (999.5 fM) and very low (reported as 5
10−37 fM), respectively, at the crossing point in Figure 4.
We conclude that increasing the antigen load from zero in a
naïve system first produces minor “acute” inflammation, which
then becomes strong inflammation as the threshold of 16.7
fM/min is transgressed. The system is then in the “chronic”mode.
Then, reducing the antigen load to far below that threshold value
does not cause a flip back to the “acute” mode even though the
corresponding TNF levels can become lower than those in the
acute mode (compare Figure 4B to Figure 4A at very low CRA
influx rates). The transition from acute mode to chronic mode
was irrevertible. In the section “Discussion,” we shall discuss
how this does not quite correspond to the irreversible transition
known for simpler dynamic systems (58).
Between antigen loads of 0.5 and 16 fM/min, the stability of
the acute mode is already limited. Minor increases in TNF lead to
a return to the acute mode, but major ones already induce a flip to
the chronic mode of inflammation. This indicates a role of noise
in TNF in inducing precocious transitions into the chronic state.
Recently, Mavroudis et al. (30) highlighted such a role of noise in
the immune response.
Switching, Irrevertible Transition, and
Fibroblast Levels
The innate immune system that we here model is complex,
and more than one variable is involved in its regulatory
loops. In Abudukelimu et al. (42), we already showed how
the steady-state fibroblast level also varied in a complex way
with antigen load (CRA influx rate). When starting at very
low antigen exposures, the naïve system followed the green line
in Figure 6A corresponding to the acute mode, with fibroblast
levels close to 3-D confluency (1,000 fM). At the CRA influx
rate of 16.7 fM/min, this stable mode ceased to exist, and
the system dropped to only one of the two stable steady-
state modes that remained, i.e., the strongly inflamed one
indicated by the red line, with ultralow fibroblast levels, well
below the 0.2.10−10 fM corresponding to a single fibroblast
per human body. In a separate run of computations, we
therefore fixed the fibroblast levels to zero, producingmore stable
steady states, but without other significant differences (as also
mentioned above).
The green dashed arrows in Figure 6 again show that the
acute-mode states were stable against substantial perturbations,
now of fibroblast levels. Below the CRA influx threshold,
perturbation of the fibroblast level to 10,000 was followed by
relaxation to the steady-state level just below 1,000 fM as did
perturbations to the 3D-confluency level of 1,000 fM (not shown
but implied). Reducing the fibroblast levels to some extent was
also followed by a relaxation back to the acute-mode steady
state, but the extent of the perturbation for which this was true
diminished as the CRA influx approached the threshold rate (of
16.7 fM/min). The perturbed fibroblast level above which the
relaxation proceeded back to the acute mode is indicated by the
blue “wobble” line in Figure 6A. For a stronger perturbation of
the fibroblast level, the system switched to the chronic mode,
as indicated by the red dashed arrows pointing down to the
corresponding red “chronic” line. Above the threshold CRA
influx, all such relaxation was to the chronic mode with ultralow
fibroblast levels.
In simple bistable systems, there is an unstable steady state
“in between” the two stable states, i.e., for a given value of the
bifurcation parameter, there is a value of the bifurcation variable
that corresponds to a state where the time derivatives of all
variables are again zero, but at least one eigenvalue is positive.
By using various starting values for the fibroblast level, we found
such unstable steady states through Copasi and have indicated
these by the dashed orange line in Figure 6. In simple bistable
systems, one can move between stable steady states by changing
the bifurcation variable just a bit across its unstable steady state
value. The figure suggests, and more detailed computations (not
shown) confirmed, that this was not the case here: the blue
“wobble” line is always below the orange unstable states line in
Figure 6A. Starting from an acute inflammation state, we had to
reduce the fibroblast level significantly below its unstable steady
state value in order to provoke “switching,” i.e., relaxation to the
chronic rather than the acute mode. Just reaching the unstable
steady-state value was not enough; the system was conservative
in that it seemed to resist the flipping between stable steady states.
When starting from the acute mode (Figure 6A), the distance
between the unstable steady states and the wobble points was
small, but when starting from the chronic mode (Figure 6B) this
distance was much larger, close to a factor of 100. Accepting
that realistically the fibroblast level cannot be brought to
concentrations in excess of 1,000 fM, chronic inflammation at
CRA influx rates between just above 1.5 fM/min (i.e., less than
one tenth of the threshold flux) and that threshold flux (16.7
fM/min) cannot be switched back at all to the acute mode by
maximum repopulation with fibroblast. Since 1.5 fM/min might
be the minimum antigen load that can be achieved in most cases,
this could imply that, although the acute to chronic transition
is not irreversible in theory, it cannot in practice be reversed,
yet another reason to call the transition “irrevertible.” Above we
showed that it cannot be reversed by reduction of antigen influx
alone, and here we show that it cannot be reversed by fibroblast
implantation alone.
This irrevertibility is a consequence of the complex non-linear
nature of the innate immunity model. The same complexity
causes more paradoxical phenomena. In the CRA influx range
between 1.5 and 16.7 fM/min, perturbation of the fibroblasts
from the chronic level to a level above the wobble line is followed
by a relaxation back to the acute mode. Paradoxically, this
relaxation passes the fibroblast–relaxation path subsequent to a
perturbation to slightly below the wobble level, which relaxes
to the chronic state (see the red and green dashed arrows at 10
fM/min in Figure 6B).
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FIGURE 6 | Fates after fibroblast intervention. In (A) acute (green line) or (B) chronic (red line) steady states (see Figure 4), healthy fibroblast levels were varied and
then used as initial states for a calculation by Copasi of the steady-state fibroblast level. This strategy was used to find (1) the healthy fibroblast level corresponding to
the unstable steady state (dashed orange line) and (2) the “wobble” fibroblast level (blue line) beyond which the systems transited to the other stable steady state, as
also indicated by the dashed arrows. For both (A) and (B), the steady state fibroblast level (in fM) is plotted vs. the CRA influx rate (in fM/min). The dotted horizontal
line at the fibroblast level of 1,000 fM corresponds to the maximum fibroblast level, which corresponds to complete space filling (3D confluency); all points above that
line are biologically (but not mathematically) infeasible. In the chronic steady states, the fibroblast levels were ultralow and, for the purpose of plotting, equated to 0.01
fM. The wobble points depended somewhat on initial states and varied somewhat between calculations, possibly due to the strong temporal dynamics of TNF.
The origin of these paradoxical behaviors resides in the
complexity of the system. The fibroblast level is only one of
the bifurcation variables. When bringing the fibroblast level just
across the magnitude of the unstable steady state, that level itself
may indeed be attracted to the other steady state, but the other
dynamic variables, such as TNF and FLC, are still at magnitudes
that favor relaxation to the original steady state. We have tested
this insight by simultaneously moving two bifurcation variables
in the direction of the transition to the other steady state, in
this case, from the chronic to the acute mode. Table 1 shows
that, whereas changing only TNF or only the fibroblast level in
this computation did not cure the chronic inflammation in silico,
their combination did. That this corresponds to cooperativity
is shown by the result (Table 1) that much stronger treatment
in terms of modulating either factor alone did not cause the
transition from chronic to acute mode.
Jumping the Bistability Barrier: Fibroblast
Proliferation
In the preceding section, we showed that merely adding a batch
of fibroblasts to our chronically inflamed model rarely switched
it back to its acute mode. This was presumably because the
added fibroblasts were subject to the toxicity of the strongly
elevated TNF and disappeared rapidly. This suggested that a
sustained influx of fibroblasts into the inflamed area might be
more successful in reverting the chronic inflammation. The heat
map in Figure 7B shows that indeed allowing fibroblasts to grow
into the system at a fixed low rate already affected chronic
Frontiers in Immunology | www.frontiersin.org 11 February 2020 | Volume 10 | Article 3091
Abudukelimu et al. Dynamics of Innate Inflammation
TABLE 1 | Computed effect on chronic inflammation of treatment with fibroblast
implantation and/or TNF reduction.
Treatment Result Cure?
TNF treatment Fibroblast implantation Fibroblast TNF
pM fM fM pM
None None 2. 10−39 49.5
None 0–200 1. 10−100 49.5 No
49.9–10 None 6. 10−245 49.5 No
49.9–10 0–200 998 0.02 Yes
None 0–400 9. 10−7 49.5 No
49.9–0 None 9. 10−100 49.5 No
The low fibroblast levels reported by the program essentially equal zero. CRA influx rate
was 1 fM/min throughout.
inflammation at low CRA influx levels, but not yet much at high
CRA influx levels. Fast fibroblasts ingrowth (i.e., above 0.3 10−2
fM/min) completely suppressed chronic inflammation at all CRA
influx rates (Figure 7B). Figure 7A shows that the low fibroblast
influx rate (10−5 fM/min) had no effect on acute inflammation,
whereas a thousand-fold faster fibroblast ingrowth suppressed
high inflammation in the acute inflammation mode altogether,
preventing the upsweep to high TNF levels at CRA influx above
16.7 fM/min (compare Figure 7A with Figure 7B).
Jumping the Bistability Barrier: Targeting
IgLC or IgE
Another component of the positive feedback loops in the innate
immunity model is the immunoglobulin light chain (IgLC), as
freely circulating light chains or, in a different incarnation of
the model, as IgE. We had already found in silico that an IgLC-
neutralizing peptide reverted chronic inflammation to its acute
counterpart in the sense of reducing the TNF level (42). It did this
only temporarily however; after some time, TNF increased again,
ultimately returning to the TNF level characteristic of chronic
inflammation. The results of the preceding section suggest an
explanation: the systemmight be trapped irrevertibly in the stable
chronic inflammation state. Accordingly, the anti-IgLC peptide
might then temporarily reduce the inflammation, but it might
be impossible for the system to escape from the attractor of the
chronic state in this way.
At three different CRA influx rates, we checked whether
indeed the state produced by addition of the peptide (which
caused the decrease in TNF level shown by the green downward
arrow in Figure 8A) was unstable. We found that for the two
cases where the peptide had lowered the TNF level, the situation
was unstable 6 h after peptide addition; where CRA influx was as
high as 3 fM/min, the TNF level was as high as in the beginning.
The red arrows show that, for all three cases, by 1 day after
peptide addition the simulated TNF level had returned to its
initial high-level characteristic of strong inflammation.
Figure 8B shows that if fibroblasts were added as well, the state
achieved 6 h after peptide addition was stable and characteristic
of reversal of the chronic inflammation to the acute mode. The
absence of a red arrow means that there was no subsequent
change. This all happened at a CRA influx rate of 0.1 fM/min. At a
FIGURE 7 | Healthy fibroblast influx and inflammation, in silico. For various
CRA influx rates and various influx rates of healthy fibroblasts, the stable
steady-state TNF level was calculated for the (A) acute and (B) chronic
inflammation modes, respectively. The TNF level as a function of CRA and
fibroblast influx rates are presented as a heat map, the color reflecting the
corresponding steady-state level of TNF (in pM), as indicated by the bar on the
right-hand side.
ten-fold higher CRA influx, the peptide addition only produced a
transient unstable state, which reverted to full inflammation by
1 day after peptide and fibroblast addition. When instead of a
single fibroblast addition fibroblasts were infused continuously,
the chronic inflammation was reversed at all three CRA influx
rates of the computations (Figure 8C). We conclude that influx
of fibroblasts stabilizes the low inflammation state induced by the
peptide drug.
DISCUSSION
Our dynamic model of the innate immune system in
inflammation (42) exhibited various features that were at
odds with the usual “watchmaker” models of metabolic pathways
(59–62). It exhibited a preference for one of two families
(modes) of states. In the present paper, we report some more
peculiar observations that the model makes and that may
well speak to innate immunity itself, such as recurrent bursts
of inflammation, hysteretic behavior, the role of an apparent
bystander (fibroblasts) in reverting the preference for the
“chronic” state, and the potential of such a bystander for making
peptide therapies definitive rather than unreliable.
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FIGURE 8 | Computed time dependence of chronic inflammation subjected to
anti-IgLC peptide therapy with or without fibroblast supplementation. The
steady-state chronic inflammation level of TNF (red circles) was computed for
CRA influxes of 0.1, 0.5, and 3.0 fM/min, respectively, each time starting from
the initial state at 30 fM/min. (A, B, C) Anti-IgLC peptide was then added to a
concentration of 1 nM. In (B), fibroblasts were added as well to a
concentration of 5 fM. In (C), fibroblast influx was started instead at a rate of
0.01 fM/min. The open black circles indicate the TNF levels attained after 6 h.
us refers to “unstable” and s to stable. Further development (if any) in time of
the TNF during the subsequent day is indicated by the red arrows. The blue
line represents the chronic inflammation steady states.
An example of how stability analysis can help understand
immune-system-related pathologies is the work by Murase
et al. (63), who reported that pathogens can destabilize the
interior balance of a model that represented pathogen–immune
interaction dynamics (63). In pharmacokinetics, steady-state
drug effect models have been used to estimate the robustness
of drug dose–response relationships and considered essential to
phase 2 drug development (64). Such a procedure should also
be relevant for the future applications of peptides interfering
with immunoglobulin light chains (40, 42, 65). These and
other examples made us employ stability and control analysis
to examine what determines the preference for the chronic
inflammation state, how strong this preference is, what the
preference implies with respect to the dynamic and hysteretic
properties of inflammation-associated diseases, whether the
preference and its implications are inescapable, and how anti-
IgLC peptide therapy might be improved.
Limitations and Ramifications
We carried out these analyses in a mathematical model of the
innate immune system rather than in an experimental model
system. We did this because the mathematical model gives
complete control and allows unlimited invasive experimentation
in silico to test ideas and concepts, whereas in vitro models
are much harder to manipulate and analyze quantitatively
and robustly. The mathematical model that we used has
been constructed by our bottom-up methodology (42). We
translated the individual processes of the known network into
reaction equations and rate equations. We then integrated these
equations in time, solved them for steady-state concentrations
and fluxes, and performed stability and control analysis using
the biochemical pathway simulator Copasi to obtain numerical
solutions (52). We confirmed the stability or lack of stability
of steady states reported by Copasi’s “stability analysis” option
by computation of the time dependence upon perturbations
away from the steady state, by analysis of the eigenvalues
of the Jacobian, by performing control analysis, by changing
the settings of the Copasi software such as step size, and
by changing the initial values of free variables. The results
suggested a robust and regular behavior of our numerical
methodology, with three possible exceptions. Firstly, in the
acute mode at a CRA influx around 16.7 fM/min, control
coefficients tended to infinity (Figures 3A,B). This was caused
by a bifurcation turning the system from a bistable to a mono-
stable system and not by a numerical insufficiency. The low
inflammation steady state jumped up to its high inflammation
steady state for an infinitesimal increase of the CRA influx rate
(see Figure 4). Secondly, the fibroblast levels reported for the
chronic mode were extremely low in absolute magnitude and
sometimes negative in value. We showed however that if the
fibroblast levels were set to zero (and left fixed or variable), the
model’s behavior remained unchanged, the positive eigenvalues
(which were associated with the fibroblast levels) disappeared,
and Copasi reported the same control coefficients. Moreover,
the summation laws of metabolic control analysis (49) were
met (see Supplementary Tables S3, S4). We conclude that the
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phenomenon is due to the autocatalytic nature of fibroblast
growth and the inability of digital computers to end up at true
zero values. The third special observation was that the stepwise
decrease of CRA influx with at each step the steady state being
computed, when followed by a stepwise increase of CRA influx,
led to a retreading of the steady states’ trajectory of the CRA
downward chronic mode rather than a progression along the
acute mode. We showed that this was not due to a numerical
anomaly either but rather to the fact that although the TNF
levels of the chronic and the acute mode crossed each other,
the fibroblast levels were highly different. We conclude that our
results are not compromised by numerical limitations.
The absence of numerical ramifications does not mean that
our results are relevant for innate immunity in practice. Due
to the very complexity of the total innate immune system, we
have had to keep our model simpler than reality. Limitations
include the inability of mast cells and B cells to proliferate,
the lack of compartmentation, the absence of many cytokines,
the simplifications in where the relevant antigens come from,
and the absence of adaptive immunity. In addition, the kinetic
equations and parameter values that we used were simple and,
though founded in realistic assumptions (42), were limited in
experimental foundation of their magnitudes.
Our earlier paper on the same model of innate inflammation
(42) contains a rationalization of the model species, model
equations, and parameter choices made. A model of this
complexity cannot at present be fully validated experimentally.
Such a validation would require hundreds of experimental
manipulations with highly accurate functional measurements
in some 10 cellular compartments that are ill-accessible
experimentally. Therefore, we have to be satisfied for the moment
with validation in the sense that experimentally observed
emergent behavior is predicted successfully by the model (10).
After all, this is the status of perhaps the best validated complex
models we know: ability to simulate the (lack of) emergent
behavior ofmutants (66).More complete experimental validation
is only possible for much simpler metabolic models such as our
E. coli ammonia assimilation model, and even then we needed
special methods to deal with uncertainties (67).
The behavior of our model is however similar to innate
immunity in practice, which is what one may consider a mild
validation: it is able to deal with microbial infections; it exhibits
acute and chronic modes with persistence of the latter; it affects
TNF strongly; and it shows that anti-FLC peptides should be
expected to have effects but that these effects are conditional
(65). The model describes fibroblast levels of up to 1 nM, which
corresponds to a realistic cell volume of 1.7 pl and contact
inhibition. Its mast cell and B cell concentrations are 10,000 and
1,000 times lower, respectively. At maximum inflammation, the
TNF levels amounted to 50 pM. This corresponds well with the
observation that TNF activates cells at picomolar concentrations,
with its receptors having one KD around 20 nM and a second
KD of 400 pM (68). The TNF levels that we predict in the
high inflammation mode of 50 pM should not yet saturate these
receptors. Serum TNF levels of healthy individuals are around
0.4 pM, with levels around 1 pM for people with inflammatory
conditions (69), which we imagine to stem from 50-fold dilution
out of inflamed areas into the blood stream. The other cytokines,
MMP7 and MMP8, occur at grossly similar levels in our model
results, in agreement with reality in serum (69). Of course these
correspondences between model predictions and reality do not
prove the model to be correct; a wrong model can lead to right
predictions. In conclusion, the model is validated in this and
our previous paper to some extent, but incompletely, by the
correspondence of its behavior to reality. Because its conclusions
are of interest, the model should be further validated and perhaps
improved in a more comprehensive future study also engaging
in new experimentation. Ultimately, one would like to achieve
a version of this model that is in close correspondence with all
experimental data in innate immunity, as well as with the other
existing mathematical models.
Because we were not estimating (fitting) model parameters
in our paper, identifiability was not an issue. Our model
predictions are based on the most reasonable parameter values
(see the rationalization in our previous paper) fixed at the onset
and not adjusted in order to obtain a better fit. Our control
analysis shows moderate control coefficients, suggesting limited
parameter identifiability. Multiple parameter values lead to the
same qualitative conclusions. This has the disadvantage that the
model parameters are not identifiable, but the advantage that
our conclusions about the in silico model should have a higher
probability of being relevant for the situation in vivo.
Moreover, themodel appears to be useful; it makes predictions
of how modifications of therapies might improve their impact,
with suggestions for applications such as in allergy treatment. It
should help that not every detail is essential for our observations
and conclusions. Important are the positive and negative
feedback loops in the innate immune system and the fact that,
for any increase in the number of fibroblasts, fibroblasts need to
be present. Adding more features of the actual innate immune
system will add more features of this type as well so that we
expect that the (in)stability aspects we modeled here will persist.
This implies that interference with the innate immune system
with medicinal drugs, such as the IgLC-binding peptide modeled
here, should be effective equally conditionally when other targets
are chosen, such as TNF (an effective target in the treatment of
rheumatoid arthritis (49, 70) or one of the MMPs.
Complex Stability of a Model of Innate
Immunity: State Trapping
A most pertinent model observation was that treatment of
the high inflammation state with anti-IgLC (anti-IgE) peptide
initially appeared to be effective in inducing a switch to the low
inflammation state, but the therapy became ineffective after a
much longer time. The present paper has clarified this. Firstly,
we verified that the model is home to two modes of stable steady
states, which overlap in terms of corresponding parameter values,
i.e., bistability was occurring. Secondly, we found that the model
is somewhat out of the ordinary; redressing the CRA influx
from the high magnitude characteristic of the strong (“chronic”)
inflammation mode all the way back to zero did not cause the
system to jump back to its acute mode.
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This transition from acute to chronic mode is what we call an
irrevertible transition. The transition is “irreversible” neither in
the sense of non-equilibrium thermodynamics (57) nor in the
sense of simpler bistable systems (49) with a single bifurcation
parameter requiring unrealistic negative values for the reverse
transition. We established that the TNF levels of the acute and
the chronic branch neither merged at low values of CRA influx
nor stayed away from each other as they do in the simple case of
bistability with a simple irreversible transition (49). They crossed
each other (compare Figure 4A to Figure 4B around CRA influx
rates of 0.0001 fM/min).
Looking at how, for the chronic mode of steady states, the
fibroblast level varied with CRA influx rate, we found that
the fibroblast level was always very close to zero and did not
recuperate. Even though the peptide drug decreased the TNF
level to a value close to that characteristic of the low inflammation
state, it did not increase the fibroblast level from the very-close-
to-zero level characteristic of the highly inflamed state back to the
high level characteristic of the low inflammation “acute” mode of
states; thereby, the peptide treatment did not completely undo
the irrevertible transition to the high inflammation state. This
suggested that increasing the concentration of fibroblasts might
be able to revert inflammation from its high chronic mode to its
low acute mode, and indeed in silico addition of fibroblasts or a
constant influx of fibroblasts was able to achieve this.
The complexity of the irrevertible transition was greater than
this however. The actual transition point from acute to chronic
and much more so that from chronic to acute did not correspond
to the magnitude of the fibroblast concentration at the unstable
state. We called the transition points “wobble points” (see the
blue lines in Figure 6). The reason for the transitions from
“chronic” back to “acute” or vice versa being determined neither
by the TNF nor by the fibroblast unstable steady-state value alone
is that the bifurcation is determined by multiple state variables
rather than one. We witnessed a complexity in our innate
immunity model that derives from its multidimensionality, with
multiple molecular and cell species determining fate. Indeed
altering both the TNF and the fibroblast levels at the same time,
we more readily switched the system (Table 1).
The chronic inflammation branch of states was particularly
robust to ordinary fluctuations and perturbations, thereby
requiring very special perturbations for in silico therapies
to be successful. Figure 6B reveals another limitation to the
revertibility of the chronic mode: for CRA influx rates between
2 and 17 fM/min, the wobble point exceeded 1,000 fM, i.e., the
maximum fibroblast concentration corresponded to filling all
space with fibroblasts. This makes the chronic state indeed an
irrevertible trap for the innate immune system.
Implications for Novel Therapies
To the extent that our model corresponds to reality, this
conclusion could have important implications for the
management of innate immunity and for potential therapies of
its diseases. Anti-IgLC peptide therapy may work temporarily
but not definitively, while sufficiently intensive fibroblast therapy
should cure definitively, but only if the cross-reactive antigen
load is smaller than what it might be. Strategic combination
therapies should prove more successful, and planning these with
the dynamic models of the type that we developed here might
be of help. Most probably, a triple therapy should be advised,
i.e., a reduction in the antigen load, some agent interfering with
a cytokine or IgLC, and a possibly sustained enhancement of
fibroblast density.
The control analysis we performed for the chronic state
confirms this difficulty for therapies of chronic inflammation.
Processes other than TNF synthesis and TNF washout exercised
no control on the TNF level in the chronic steady state,
confirming that there was no target for which limited interference
could affect inflammation. If anti-TNF is to work definitively,
very high doses should be required. This was different for the
acute mode of inflammation, where a great many processes
exercised such control, which suggests that by focusing on any
of the many processes with the high control coefficients one
should be able to design many medicinal drugs preventing the
inflammation from becoming chronic. Also here prevention
should be much better than therapy.
Our prediction that ultimately anti-IgLC therapy alone may
not work may not quite be realistic. In actual cases, there will
always be ingrowth of fibroblasts, and therefore one would obtain
in any practice the situation of a combined therapy with fibroblast
ingrowth and anti-IgLC peptide. Our conclusions should still
be taken to mean then that activation of fibroblast ingrowth
(or in practice activation of corresponding stem cells) should
be considered a strong candidate adjuvant therapy. Another
ramification is that with time after the first challenge, the adaptive
immune system will become active and take over much of
the role of the innate immune system. Therefore, the flares of
microbial growth and the switch to chronic inflammation may
be moderated by the adaptive immune system taking away the
antigenic stimulation that lies at their bases.
A Special Type of Bistability
There are many models of bistable dynamic systems. The present
model of innate immunity is however special. The transition
to the chronic state is irrevertible in the sense that (1) the
chronic mode does not revert to the acute mode, not even at
the point where both the bifurcation parameter CRA influx
and the bifurcation variable TNF are the same for the acute
and the chronic mode, (2) this is not an irreversible transition
due to the fact that the bifurcation parameter cannot become
negative, (3) TNF reduction cannot definitively revert the acute
to chronic transition, (4) often fibroblast addition cannot do
this either because the concentration of fibroblasts cannot
exceed its physical limit, and (5) dual intervention can revert
the irrevertible transition, but only in special ways, sometimes
requiring a third intervention (e.g., fibroblasts, anti-IgLC peptide,
antigen level).
Robustness of Innate Immunity
We found that the type, more than the magnitude, of the
inflammatory response depended on the influx of CRA protein.
Below a certain threshold level, the cross-reactive antigen did not
elicit much of an inflammatory response, i.e., the steady-state
TNF and fibroblast levels were low and high, respectively, and
hardly affected by the CRA influx rate. Above a certain threshold
level, varying the CRA influx did not affect much the steady-state
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magnitudes of these two variables either, but now they were low
and high, respectively. At the transition, there was a very sudden
increase in TNF level and an equally sudden drop in fibroblast
level. The control analysis for the acute branch confirmed this.
The TNF and fibroblast levels were fairly insensitive to the influx
of cross-reactive antigen throughout but became ultrasensitive at
and around the transition point. The control coefficients were
quite different for the chronic branch. There they were moderate
throughout; there was no ultra-sensitivity anywhere. Our heat
map of the dependence of the TNF levels on both the CRA influx
rate and the fibroblast influx rate confirmed the step transition,
now as a function of both the CRA influx rate and the fibroblast
influx rate. We conclude that the chronic inflammation branch
of the model is highly robust all over. The acute branch is also
robust, except near and beyond the critical CRA influx where it
transits to the chronic inflammation branch. We are here finding
the emergence of phenotypic stability in the face of perturbations
of physiological states, with two alternative such states, i.e., acute
and chronic inflammation, phenotypic bistability therefore.
An exception was found for the case where the model’s innate
immunity was activated by a bacterial infection. There we found
a virtually stable state after the immunity had dealt with the
infection, but every now and then bacteremia seemed to recur.
When we tried to cure this (as always, in silico) with a sustained
influx of antibacterial protease, we found that this seemed to
aggravate the situation. The frequency of the spurious emergence
of bacteria increased rather than decreased, although indeed the
amplitude decreased. Only at high protease influx rates did the
pulses of bacterial growth vanish. The model of innate immunity
was only marginally stable except when there was excess protease.
This may be of interest when trying to understand the re-
emergence of bacterial pathogens after apparent silence, such
as in the case of tuberculosis. These cases of re-emergence
occurred without drug resistance arising and without antigenic
variation (71), two effects which in reality will add to the effect
modeled here.
An Important Role for Bystander Cells
The stroma of tissues contains fibroblasts. These cells might seem
to serve household functions only; they manufacture protein
fibers and synthesize extracellular matrix and collagen. They also
fill up the space of the tissue, and when there is empty such space,
they grow until they become contact-inhibited again, ensuring
filling of the tissue space. In this process, the fibroblasts secrete
and respond to growth factors. We made this tissue regeneration
process operational in silico by including the simulation of the
regrowth of healthy fibroblasts. The other side of the same coin,
i.e., the innate immune system’s response to the growth and
influx of healthy fibroblasts, is a novel topic, which we also
tried to deal with here. In our simulations, a paradox then
emerged. Rather than being a background/household factor,
healthy fibroblasts seemed to be essential for switching the system
from a disease state to a healthy state. Without their activity,
anti-IgLC, which was considered a therapy in silico, did not
produce a permanent effect. For the effect of anti-IgLC to be
permanent, healthy fibroblasts had to be fluxed into the system
or a sufficiently high single dose of these cells had to be given.
Because our model was also simulating the lymph system and
its tendency to cleanse tissue, the anti-IgLC peptide was only
present temporarily in the system, whereas even a single dose
of fibroblasts generated progeny and thereby provided for a
continuous influx of more fibroblasts. The resolution of the
paradox that we mentioned above is complex but may reside in
the fact that healthy fibroblasts secrete both anti-inflammatory
(such as MMP8) and pro-inflammatory (such as MMP7) factors,
whereas dying fibroblasts secrete more pro-inflammatory factors
(72, 73). Inflammation causes the number of dying fibroblasts
to increase, which then puts in motion a positive feedback loop.
More research should put the details of this explanation in place
or replace the explanation with a better alternative.
Herewith healthy fibroblasts are predicted to have a
therapeutic effect. Healthy fibroblasts alone should sometimes
be able to cure disease, but only when the immune disease is
chronic. In our model, ingrowth of fibroblasts had little effect
when the system was in the acute inflammation branch. The
acute mode of inflammation is already saturated with healthy
fibroblasts, and this is why the curves with and without fibroblast
ingrowth showed overlapping TNF activity (Figure 7A for CRA
influx rates below 17 fM/min). However, when TNF was there
as output response of the chronic inflammation, the TNF curves
with and without fibroblast ingrowth showed a different outcome
at most CRA influx rates (Figure 7B).
This Model’s Novelty
There are quite a few mathematical models of immunity, but
fewer such models of innate immunity. Other than the one we
developed and used here, there are no mathematical models that
address the (lack of) ability of a peptide drug interfering with
IgLC (or IgE) to revert chronic inflammation definitively. This
non-robust ability has been the subject of a set of experimental
studies by one of the authors of the present paper [(38, 39, 65);
see also (41)] and served as the inspiration and guidance for both
the present and the previous paper (42). The present paper comes
with another novelty however; it provides for an explanation of
the faltering effects of this type of peptide as well as a number
of suggestions on how to improve the robustness of this type of
therapy. Other than just in the bistable nature of innate immunity
that has also been discussed by other models although not for this
peptide, the novel explanation resides in the special irreversibility
of the transition from acute to chronic. Novel is also the
demonstration that a dual or even triple intervention should be
needed to revert the system from the chronic to the acute state,
i.e., reduction in antigen load, the peptide interference with the
IgLC, and the implantation of fibroblasts. The consideration of
the influence of fibroblast levels, in relationship with their levels
at full cell confluency, is also new. Cockrell and An (74) recently
also reached the conclusion that multi-dented therapies are
needed to deal with sepsis. They built a reinforcement learning
workflow for designing corresponding therapies (29), but they
do not analyze the source of the complexity in the special type of
irreversibility nor do they address the use of anti-FLC peptides.
Some of the other models present in silico clinical trials in
phenomenological (26, 75) or more mechanistic target (27) terms
and address anti-TNF agents, yet other models address the role
of mimicry in autoimmunity (76). Pigozzo reviewed the various
types of models in existence and then developed their own
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(22). The model developed by Smith dealt with pneumococcal
infections of the lung but did not analyze complex stability
properties nor did it report flares of resurgent inflammation (77).
Sontag developed an immunology model that exhibited complex
stability properties, but this model was phenomenological, i.e.,
formulated in terms of a few abstract properties rather than being
mechanistic as the model used here (37). Its main application was
the interesting non-unique relationship between immunological
activity and tumorigenesis. Eftimie and Hamam modeled the
non-robustness of tumor cell elimination by macrophages due to
the presence of two types of CD4+ T cells (35). They performed
a sensitivity analysis and observed highly complex bistability, but
not of the type discovered here, and in a four-variable model. In
a well-documented paper, Qomlaqi et al. (36) modeled adaptive
immunity in immunotherapy and showed how efficacy depended
on dosage dynamics, but without analyzing the complex stability
of the system. Kumar developed a three-component model that
simulated the dynamic response of the immune system to a
pathogen (54). Theirmodel predicted oscillations of the pathogen
level, which were similar to the “flares” of recurrent inflammation
observed by our simulations, without reporting however the
paradoxical increase in frequency with protease treatment. Their
model was small enough to perform an analytical analysis of its
eigenvalues. This was an advantage for developing a higher-level
concept, but failed for us, where we needed more detail which
we could handle by numerical analyses using Copasi. Reynolds
et al. did an extensive bifurcation analysis of a model with four
somewhat abstract variables (26). They also found bistability and
a jump from low to high inflammation for increasing antigen load
(represented by the growth rate of the pathogen) and a different
trajectory when the antigen load was decreased subsequently.
Activation of their anti-inflammation variable also had a time-
dependent effect. Some of the same authors also published amore
detailed and mechanistic model successfully predicting transient
changes in cytokines upon the onset of inflammation (78).
Neither paper addressed the same complexity of the irrevertible
transition to the chronic state nor the difficulties of reverting
back to the acute mode of inflammation such as through
anti-IgLC peptide. Mavroudis et al. (30) recently developed a
phenomenological model of immunity in which tissue damage
played a role, as in our model of 1 year before them (42). They
however also highlighted the role of noise or cell–cell diversity
(79), which we do not do here, although Figure 4A suggests that
noise could be important.
Our elucidation of the role of a type of bistability that has
a complex irrevertibility, the introduction of wobble points
in addition to unstable steady state, the shift away from an
anti-TNF agent to an anti-IgE/anti-IgLC peptide, the explicitness
in terms of molecules and mechanisms, the control analysis and
concomitant drug target identification, and the role of fibroblasts
as much-involved bystander cells are new as compared to the
existing mathematical models.
CONCLUSION
The dynamic model of innate immunity analyzed here can
help to understand various complex phenomena related
to inflammation and suggest new multi-dented therapies.
Further tuning of the model by interacting with new
experimental data and uncertainty quantification (80) should
show whether the understanding suggested in this paper
is definitive.
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